<DOC>
	<DOCNO>NCT00572182</DOCNO>
	<brief_summary>RATIONALE : MK0752 may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose MK0752 treat young patient recurrent refractory CNS cancer .</brief_summary>
	<brief_title>MK0752 Treating Young Patients With Recurrent Refractory CNS Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To estimate maximum tolerate dose ( MTD ) recommend phase II dose MK0752 administer 3 consecutive day every 7 day 28 day course young patient recurrent refractory CNS malignancy ( Dosing regimen 1 - close accrual 2/23/2010 ) . - To estimate MTD recommend phase II dose MK0752 administer weekly 28 day course young patient recurrent refractory CNS malignancy ( Dosing regimen 2 ) . - To compare MK0752 systemic exposure attain dosage level different dose regimen . Secondary - To characterize pharmacokinetics MK0752 . - To document describe toxicity associate MK0752 . - To preliminarily define antitumor activity MK0752 within confines phase I set . OUTLINE : This multicenter , dose-escalation study . Patients receive oral MK0752 daily day 1-3 , 8-10 , 15-17 , 22-24 ( dose regimen 1 - close accrual 2/23/2010 ) day 1 , 8 , 15 , 22 ( dose regimen 2 ) . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Treatment may extend 19 course patient benefit treatment . Patients undergo blood sample collection periodically pharmacokinetic study . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary CNS tumor Patients intrinsic brain stem tumor require histologic verification , must radiographic evidence progression Recurrent disease refractory standard therapy No histologically benign brain tumor ( e.g. , lowgrade glioma ) PATIENT CHARACTERISTICS : Karnofsky performance status ( PS ) Lansky PS 60100 % Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Absolute neutrophil count ≥ 1,000/μL Platelet count ≥ 100,000/μL ( unsupported ) Hemoglobin ≥ 8 g/dL ( RBC transfusion allow ) Creatinine clearance OR glomerular filtration rate ≥ 70 mL/min OR serum creatinine base age follow : 0.8 mg/dL ( ≤ 5 year age ) 1.0 mg/dL ( &gt; 5 ≤ 10 year age ) 1.2 mg/dL ( &gt; 10 ≤ 15 year age ) 1.5 mg/dL ( &gt; 15 year age ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) age ALT ≤ 2.5 time ULN age Albumin ≥ 2.5 g/dL Sodium , potassium , magnesium , calcium normal Patients neurological deficit eligible provide deficit stable ≥ 2 week prior study registration No clinically significant systemic illness ( e.g. , serious infection significant cardiac , pulmonary , hepatic , organ dysfunction ) would compromise patient 's ability tolerate study therapy would likely interfere study procedure result No known hypersensitivity MK0752 PRIOR CONCURRENT THERAPY : Recovered acute toxic effect prior therapy At least 3 week since prior myelosuppressive anticancer chemotherapy ( 6 week nitrosoureas ) At least 7 day since prior investigational biologic agent At least 3 week since prior investigational biologic agent prolonged halflife patient experience ≥ grade 2 myelosuppression treatment course precede discontinuation therapy At least 3 half life since prior monoclonal antibody therapy At least 6 month since prior total body irradiation craniospinal radiotherapy At least 6 week since prior substantial bone marrow irradiation At least 2 week since prior local palliative radiotherapy ( small volume ) At least 6 month since prior allogeneic bone marrow transplantation ( BMT ) No evidence active graft versus host disease At least 3 month since prior autologous BMT stem cell transplantation At least 7 day since prior hematopoietic growth factor ( filgrastim [ GCSF ] , sargramostim [ GMCSF ] , erythropoietin ) ( 14 day longacting formulation ) No prior MK0752 No concurrent enzymeinducing anticonvulsant drug ( EIACDs ) No concurrent anticancer investigational drug therapy Concurrent dexamethasone allow provided patient stable decrease dose ≥ 2 week prior study registration</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>recurrent childhood brain stem glioma</keyword>
	<keyword>childhood central nervous system germ cell tumor</keyword>
	<keyword>recurrent childhood cerebellar astrocytoma</keyword>
	<keyword>recurrent childhood cerebral astrocytoma</keyword>
	<keyword>childhood high-grade cerebral astrocytoma</keyword>
	<keyword>childhood choroid plexus tumor</keyword>
	<keyword>childhood craniopharyngioma</keyword>
	<keyword>recurrent childhood ependymoma</keyword>
	<keyword>recurrent childhood medulloblastoma</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>recurrent childhood pineoblastoma</keyword>
	<keyword>recurrent childhood supratentorial primitive neuroectodermal tumor</keyword>
	<keyword>childhood atypical teratoid/rhabdoid tumor</keyword>
	<keyword>childhood spinal cord neoplasm</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>recurrent childhood visual pathway hypothalamic glioma</keyword>
	<keyword>childhood grade III meningioma</keyword>
</DOC>